NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin
Estimated value
—
Awarded value
—
Suppliers
36
Lots
9
Published
22 Jul 2021
Description
National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Scope
- Reference
- CM/PHS/17/5550
- Commercial tool
- Standalone contract
- Contract dates
- 30 Jun 2021 to 31 Mar 2025
- Main category
- goods
- CPV classifications
- 33651520
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Security of Supply | 30% | quality | — |
| usability | 10% | quality | — |
| — | 60% | price | — |
| Usability | 10% | quality | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 36 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 9 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg) | — | cancelled |
| 2 | Lot 2: 10% Intravenous Immunoglobulin (10% IVIg) | — | cancelled |
| 3 | Lot 3: Subcutaneous Immunoglobulin (SCIg) | — | cancelled |
| 4 | Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg) | — | cancelled |
| 6 | Lot 6: 10% Intravenous Immunoglobulin (10% IVIg) | — | cancelled |
Award 1· 1 supplier
Awarded —
Award 2· 1 supplier
Awarded —
Award 3· 1 supplier
Awarded —
Award 4· 1 supplier
Awarded —
Award 5· 1 supplier
Awarded —
Award 6· 1 supplier
Awarded —
Award 7· 1 supplier
Awarded —
Award 8· 1 supplier
Awarded —
Award 9· 1 supplier
Awarded —
Award 10· 1 supplier
Awarded —
Award 11· 1 supplier
Awarded —
Award 12· 1 supplier
Awarded —
Award 13· 1 supplier
Awarded —
Award 14· 1 supplier
Awarded —
Award 15· 1 supplier
Awarded —
Award 16· 1 supplier
Awarded —
Award 17· 1 supplier
Awarded —
Award 18· 1 supplier
Awarded —
Award 19· 1 supplier
Awarded —
Award 20· 1 supplier
Awarded —
Award 21· 1 supplier
Awarded —
Award 22· 1 supplier
Awarded —
Award 23· 1 supplier
Awarded —
Award 24· 1 supplier
Awarded —
Award 25· 1 supplier
Awarded —
Award 26· 1 supplier
Awarded —
Award 27· 1 supplier
Awarded —
Award 28· 1 supplier
Awarded —
Award 29· 1 supplier
Awarded —
Award 30· 1 supplier
Awarded —
Award 31· 1 supplier
Awarded —
Award 32· 1 supplier
Awarded —
Award 33· 1 supplier
Awarded —
Award 34· 1 supplier
Awarded —
Award 35· 1 supplier
Awarded —
Award 36· 1 supplier
Awarded —
Total lots
9
Awarded
0
Estimated total
—
Awarded total
—
Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg)
Start
30 Jun 2021
End
31 Mar 2025
Estimated
—
CPV
Lot 2: 10% Intravenous Immunoglobulin (10% IVIg)
Start
—
End
—
Estimated
—
CPV
Lot 3: Subcutaneous Immunoglobulin (SCIg)
Start
—
End
—
Estimated
—
CPV
Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg)
Start
—
End
—
Estimated
—
CPV
Lot 6: 10% Intravenous Immunoglobulin (10% IVIg)
Start
—
End
—
Estimated
—
CPV
Lot 5: 5% Intravenous Immunoglobulin (5% IVIg)
Start
—
End
—
Estimated
—
CPV
Lot 7: Subcutaneous Immunoglobulin (SCIg)
Start
—
End
—
Estimated
—
CPV
Lot 9: Anti-D Immunoglobulin (Anti-D)
Start
—
End
—
Estimated
—
CPV
Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg)
Start
—
End
—
Estimated
—
CPV
Other contracts from The NHS Commissioning Board (operating under the name of NHS England)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Octapharma Limited· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B) | contract | £72k | 12 Mar 2025 |
| NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin | contract | — | 20 Jan 2025 |
| Human Derived Blood Products | contract | — | 28 Aug 2024 |
| NHS Framework - Blood Disorders including Haemophilia A and B - July 2024 | contract | — | 11 Jun 2024 |
| Octapharma Ltd - Octaplas LG | contract | £53k | 14 Jun 2023 |
| Octaplex Treatment | contract | £100k | 10 May 2023 |
| Blood product required for the treatment of TTP patients | contract | £98k | 03 Aug 2022 |
| NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B | contract | — | 04 Jul 2022 |
| Human Normal Immunoglobulin and Anti-D Immunoglobulin | contract | £64.3m | 23 Jul 2021 |
| NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga) | contract | — | 11 Jun 2021 |